Cite
Innocenti I, Rossi D, Trapè G, et al. Clinical, pathological, and biological characterization of Richter syndrome developing after ibrutinib treatment for relapsed chronic lymphocytic leukemia. Hematol Oncol. 2018;doi: 10.1002/hon.2502.
Innocenti, I., Rossi, D., Trapè, G., Autore, F., Larocca, L. M., Gomes, V., Cerri, M., Falcucci, P., Sica, S., Gaidano, G., & Laurenti, L. (2018). Clinical, pathological, and biological characterization of Richter syndrome developing after ibrutinib treatment for relapsed chronic lymphocytic leukemia. Hematological oncology, . https://doi.org/10.1002/hon.2502
Innocenti, Idanna, et al. "Clinical, pathological, and biological characterization of Richter syndrome developing after ibrutinib treatment for relapsed chronic lymphocytic leukemia." Hematological oncology vol. (2018). doi: https://doi.org/10.1002/hon.2502
Innocenti I, Rossi D, Trapè G, Autore F, Larocca LM, Gomes V, Cerri M, Falcucci P, Sica S, Gaidano G, Laurenti L. Clinical, pathological, and biological characterization of Richter syndrome developing after ibrutinib treatment for relapsed chronic lymphocytic leukemia. Hematol Oncol. 2018 Feb 27; doi: 10.1002/hon.2502. Epub 2018 Feb 27. PMID: 29484684.
Copy
Download .nbib